EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 3b

Ensembl ID : ENSCCRG00000013316
Gene Symbol: ATP1B3B
1 Cross references
227 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3b

Ensembl ID : ENSCCRG00000026730
Gene Symbol: ATP1B3B
1 Cross references
227 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCCRG00000045169
Gene Symbol: BRAF
1 Cross references
216 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCCRG00000016422
Gene Symbol: BRAF
1 Cross references
216 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSCCRG00000022373
Gene Symbol: BCL2
1 Cross references
169 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSCCRG00000022363
Gene Symbol: BCL2
1 Cross references
169 Possible Orthologues:

Bcl2 Apoptosis Regulator A

Ensembl ID : ENSCCRG00000076643
Gene Symbol: BCL2A
1 Cross references
143 Possible Orthologues:

Bcl2 Apoptosis Regulator A

Ensembl ID : ENSCCRG00000060652
Gene Symbol: BCL2A
1 Cross references
143 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCCRG00000073292
Gene Symbol: BCL2L1
1 Cross references
226 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCCRG00000074689
Gene Symbol: BCL2L1
1 Cross references
226 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSCCRG00000036473
Gene Symbol: BCL2L10
1 Cross references
128 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCCRG00000048940
Gene Symbol: CFTR
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).